| Literature DB >> 34163405 |
Janice M Kan1, Mbathio Dieng2, Phyllis N Butow3,4, Shab Mireskandari1, Stephanie Tesson1, Scott W Menzies5,6, Daniel S J Costa7,8, Rachael L Morton2,9, Graham J Mann9,10, Anne E Cust9,11, Nadine A Kasparian12,13.
Abstract
Purpose: Psychological interventions targeting fear of cancer recurrence (FCR) are effective in reducing fear and distress. Process evaluations are an important, yet scarce adjunct to published intervention trials, despite their utility in guiding the interpretation of study outcomes and optimizing intervention design for broader implementation. Accordingly, this paper reports the findings of a process evaluation conducted alongside a randomized controlled trial of a psychological intervention for melanoma patients.Entities:
Keywords: fear cancer recurrence; intervention; melanoma; process evaluation; psychological stress; survivorship
Year: 2021 PMID: 34163405 PMCID: PMC8215538 DOI: 10.3389/fpsyg.2021.661190
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Figure 1Process evaluation framework. Adapted from the UK Medical Research Council framework for conducting and reporting process evaluation studies (Moore et al., 2015). Key components of the process evaluation are in green boxes. Investigation of these components is shaped by clear descriptions of the intervention and its causal assumptions. Implementation refers to how the intervention was delivered, and mechanisms of impact refers to how the intervention produced change. The dotted lines indicate the relations between context, the intervention, implementation, mechanisms, and outcomes.
Figure 2Schedule and timing of individual psychology telephone sessions and study survey assessments. HRC, High Risk Clinic.
Content of telehealth-based psychotherapeutic sessions and the proportion of participants who received this content.
| Assessment and melanoma history and experiences | 95% | – | – | |
| Discussion of HRC appointment | ||||
| Concerns around next appointment | 48% | 25% | 14% | |
| Update of most recent appointment | – | 99% | 100% | |
| Review of last phone session | – | 81% | 88% | |
| Resource content (MQA booklet) | Types of melanoma | 30% | 3% | 3% |
| Diagram of melanoma diagnosis statistics | 13% | 1% | 3% | |
| Melanoma and genetic factors | 12% | 3% | – | |
| Skin self-examination | 30% | 4% | 4% | |
| The role of vitamin D | 9% | 1% | – | |
| Sun exposure | 13% | 1% | – | |
| Unmet information needs | Prognosis | 21% | 3% | – |
| Type of melanoma | 11% | 4% | – | |
| Genetic risk | 12% | – | 4% | |
| Sun exposure/sun screen | 17% | 1% | – | |
| Skin self-examination | 18% | 3% | 3% | |
| Risk to children due to genetic or other factors | 24% | 1% | 1% | |
| Psycho-therapeutic techniques | Worry postponement | 5% | 8% | 6% |
| Detached mindfulness | 3% | 8% | 11% | |
| Referral for further psychological care | 5% | 7% | 15% | |
| Sleep | 9% | 10% | 7% | |
| Anxiety | 11% | 3% | 6% | |
| Depression | 4% | 3% | 6% | |
| Stress | 8% | 10% | 4% | |
| Experience of intervention participation and feedback | – | – | 85% | |
Dash (–) indicates content not covered.
MQA, Melanoma: Questions and Answers.
Mean perceived satisfaction, benefit, and difficulty of study components. Each component was rated from 0 (“not at all”) to 10 (“extremely”).
| Control group | 6.75 (2.61) | 6.13 (2.73) | 1.45 (2.25) | |
| Intervention group | 7.87 (2.34) | 7.52 (2.44) | 1.00 (1.88) | |
| 7.93 (2.29) | 7.48 (2.42) | 0.99 (1.85) | ||
| Psychotherapeutic sessions | 7.70 (2.81) | 7.08 (3.06) | 1.80 (2.55) | |
| Overall study participation | 7.79 (2.33) | 7.28 (2.65) | 1.51 (2.44) |
“Melanoma: Questions and Answers psycho-educational resource,” “Psychotherapeutic sessions via telehealth,” and “Overall study participation” refer to those in the intervention group only. Intervention group n = 67, Control group n = 77.
Perceived effects of participation in the intervention (n = 67), with ratings from 0 (“strongly disagree”) to 4 (“strongly agree”).
| Talk more openly with my High Risk Melanoma Clinic doctor and ask questions when I need to | 2.90 (0.89) |
| Know how often it is recommended that I check my skin | 2.88 (0.75) |
| Better understand my risk of developing another melanoma | 2.87 (0.78) |
| Know more about the recommended ways to check my skin and what to look | 2.85 (0.74) |
| Feel less worried about my High Risk Melanoma Clinic appointments | 2.63 (0.81) |
| Find the information I need to cope as best as I can with melanoma | 2.63 (0.76) |
| Talk more openly with my family about melanoma | 2.60 (0.78) |
| Feel more confident in my ability to cope with worries or concerns I have about melanoma | 2.58 (0.74) |
| Understand why I feel the way I do about my melanoma risk | 2.57 (0.74) |
| Feel more confident in my ability to cope with worries or concerns in general | 2.46 (0.75) |
| Find the emotional support I need to cope as best as I can with melanoma | 2.40 (0.84) |
| Find other services that may be helpful for me or my family | 2.39 (0.72) |
| Feel more confident to use coping strategies such as Detached Mindfulness | 2.31 (0.82) |
| Get emotional help and support about issues unrelated to my melanoma risk | 2.21 (0.75) |
Mean perceived helpfulness ratings for each component of Melanoma: Questions and Answers (n = 66), with ratings from 0 (“not at all helpful”) to 3 (“very helpful”).
| Different types of melanoma | 2.35 (0.81) |
| Monitoring moles for change | 2.35 (0.76) |
| Risk of developing melanoma presented in 100-person risk diagrams | 2.21 (0.83) |
| Skin self-examination | 2.33 (0.74) |
| Genetics and family history | 2.17 (0.80) |
| Sun protection after a melanoma diagnosis | 2.18 (0.88) |
| Vitamin D | 2.09 (0.86) |
| How melanoma can affect the way I feel | 1.91 (0.87) |
| Coping with melanoma | 1.92 (0.94) |
| Living with the fear that melanoma may come back | 1.74 (0.87) |
| Quotes and messages from people who have had melanoma | 1.62 (0.96) |
Reported use and perceived helpfulness of the tools included in Melanoma: Questions and Answers (n = 69).
| Skin self-examination guide | 73% | 71% |
| Moles and spots record | 62% | 62% |
| UV index explainer | 44% | 54% |
| Question prompt list | 46% | 44% |
| Menu of coping strategies | 38% | 44% |
| Checklist for recognizing signs of stress | 32% | 38% |
| Future melanoma appointments | 29% | 38% |
| List of useful websites and services | 26% | 38% |
| Diagnosis and treatment record | 26% | 35% |
| Appointment calendars | 25% | 30% |
| SunSmart app | 19% | 30% |
Multiple linear regression examining potential moderators of intervention effect (n = 61).
| Participant sex | −0.65 | −3.24, 1.95 | −0.07 | 0.620 | 0.41 |
| Time since last melanoma diagnosis | 0.00 | −0.02, 0.01 | −0.03 | 0.853 | 0.06 |
| Baseline FCRI Severity score | −0.17 | −0.33, −0.01 | −0.28 | 7.02 | |
| Satisfaction with the psycho-educational resource, M | 0.00 | −0.58, 0.58 | 0.00 | 0.991 | 0.00 |
| Thoroughness of engagement with the psycho-educational resource | 0.05 | −1.13, 1.23 | 0.01 | 0.930 | 0.01 |
| Change in melanoma-related knowledge | 0.03 | −0.21, 0.26 | 0.03 | 0.816 | 0.09 |
| Total duration of psychotherapy sessions | 0.00 | −0.02, 0.02 | 0.00 | 0.984 | 0.00 |
| Satisfaction with psychotherapy sessions | 0.17 | −0.29, 0.63 | 0.11 | 0.462 | 0.90 |
Significant results in bold typeface. CI, confidence interval.
Summary of the main findings of the process evaluation.
| Reach | • Of the 346 eligible patients, 183 (53%) consented into the trial. In the time between consent and randomization, 19 participants (10%) withdrew or did not return their baseline questionnaire. |
| Dose delivered | • Of those who participated in the sessions ( |
| Dose received | • Most Session 1 discussions (95%) included assessment and exploration of the participant's melanoma history, as well as concerns about one's upcoming HRC appointment. |
| Fidelity | • Fidelity of the psychotherapeutic sessions to the intervention manual was high (88%), with high inter-rater reliability between the two assessors (87%). |
| Barriers | • Both groups reported little difficulty engaging with the educational resources. |
| Participant satisfaction | • Satisfaction scores for the Cancer Council |
| Perceived benefits | • Perceived benefit ratings for the |
| Moderators | • Only one of the hypothesized factors—baseline FCRI Severity score—was found to moderate intervention effect (i.e., change in FCRI Severity scores from baseline to 6-month follow-up), with higher FCRI Severity scores at baseline associated with a greater decrease in FCR severity at 6-month follow-up. |
| Contamination | • External sources of information accessed by participants during the study included internet sites, participants' general practitioner, and family and friends. Reported access to additional information sources did not differ between groups. |
Clinical recommendations based on outcomes of the process evaluation.
| The psychological intervention was delivered as intended (high fidelity) and was well-received by participants. | • Implementation of the psychological intervention, into routine clinical care for Stage 0–II melanoma patients at high risk of new primary disease. |
| Satisfaction and perceived benefits of the educational resources ( | • In resource-limited environments, offering two resources to patients—one that provides brief information about melanoma (i.e., |
| Participants who received the intervention reported greater satisfaction with the Cancer Council booklet, compared with participants who received usual care. Intervention participants also perceived the quality of information and support throughout the study as greater than participants in the control group. | • Psychologist support is recommended in conjunction with informational and psycho-educational resources. |
| Number and duration of telehealth sessions with a psychologist varied between participants in the intervention group. | • Up to three psychology sessions is likely to be sufficient for most Stage 0-III melanoma patients. |
| Nearly all intervention participants engaged in the psychology sessions. Distance-delivered sessions provided | • Trained mental health professionals such as psychologists should be included as part of the clinical care team. |
| Baseline fear of cancer recurrence was the only significant moderator of intervention effect. | • Routine FCR screening for all Stage 0–II melanoma patients prior to dermatological appointments may assist in identifying those people likely to derive the greatest benefit from interventions targeting FCR. |